ProShare Advisors
RPRX icon

ProShare Advisors’s Royalty Pharma RPRX Stock Holding History

ProShare Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$815K Sell
14,542
-4,623
-24% -$241K ﹤0.01% 859
2026
Q1 		$919K Buy
19,165
+294
+2% +$12.9K ﹤0.01% 818
2025
Q4 		$729K Buy
18,871
+3,462
+22% +$132K ﹤0.01% 932
2025
Q3 		$544K Sell
15,409
-332
-2% -$12K ﹤0.01% 1061
2025
Q2 		$567K Sell
15,741
-3,807
-19% -$126K ﹤0.01% 1056
2025
Q1 		$609K Sell
19,548
-1,495
-7% -$47.4K ﹤0.01% 993
2024
Q4 		$537K Sell
21,043
-5,438
-21% -$144K ﹤0.01% 1232
2024
Q3 		$749K Sell
26,481
-1,366
-5% -$37.8K ﹤0.01% 909
2024
Q2 		$734K Sell
27,847
-3,458
-11% -$95.9K ﹤0.01% 817
2024
Q1 		$951K Buy
31,305
+2,764
+10% +$81.5K ﹤0.01% 801
2023
Q4 		$802K Sell
28,541
-807
-3% -$22.2K ﹤0.01% 818
2023
Q3 		$797K Buy
29,348
+348
+1% +$10.3K ﹤0.01% 767
2023
Q2 		$891K Sell
29,000
-1,724
-6% -$58.4K ﹤0.01% 754
2023
Q1 		$1.11M Sell
30,724
-11,377
-27% -$422K ﹤0.01% 711
2022
Q4 		$1.66M Sell
42,101
-501
-1% -$20.9K 0.01% 650
2022
Q3 		$1.71M Buy
42,602
+2,778
+7% +$119K 0.01% 643
2022
Q2 		$1.67M Sell
39,824
-13,142
-25% -$539K 0.01% 671
2022
Q1 		$2.06M Sell
52,966
-16,469
-24% -$647K ﹤0.01% 712
2021
Q4 		$2.77M Sell
69,435
-30,176
-30% -$1.17M 0.01% 696
2021
Q3 		$3.6M Buy
99,611
+25,899
+35% +$1.01M 0.01% 580
2021
Q2 		$3.02M Buy
73,712
+18,398
+33% +$783K 0.01% 627
2021
Q1 		$2.41M Sell
55,314
-6,118
-10% -$290K 0.01% 642
2020
Q4 		$3.08M Buy
+61,432
New +$2.61M 0.01% 532

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ProShare Advisors's RPRX Position: Q2 2026 in Review

ProShare Advisors reduced its Royalty Pharma (RPRX) stake by 24% in Q2 2026, selling an estimated $241K and leaving 14,542 shares worth $815K. The position accounts for ﹤0.01% of the portfolio, ranked #859.

ProShare Advisors first reported a position in RPRX in Q4 2020 and has held it in 23 quarters since. The position peaked at $3.6M in Q3 2021. 642 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • ProShare Advisors held 14,542 shares of Royalty Pharma worth $815K as of Q2 2026.
  • ProShare Advisors sold 4,623 Royalty Pharma shares in Q2 2026, an estimated $241K.
  • Royalty Pharma made up ﹤0.01% of ProShare Advisors's portfolio in Q2 2026, its #859 holding.
  • ProShare Advisors first reported a position in Royalty Pharma in Q4 2020 and has held it in 23 quarters since.
  • ProShare Advisors's Royalty Pharma position peaked at $3.6M in Q3 2021.
  • 642 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on ProShare Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.